Should I buy or sell Rezolute stock right now?

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Rezolute in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" RZLT shares. View RZLT analyst ratings or view top-rated stocks .

What is Rezolute's stock price target for 2024?

5 brokerages have issued 12-month target prices for Rezolute's shares. Their RZLT share price targets range from $5.00 to $14.00. On average, they predict the company's share price to reach $8.80 in the next twelve months. This suggests a possible upside of 166.7% from the stock's current price. View analysts price targets for RZLT or view top-rated stocks among Wall Street analysts .

How have RZLT shares performed in 2024?

Rezolute's stock was trading at $0.9925 at the beginning of 2024. Since then, RZLT shares have increased by 232.5% and is now trading at $3.30. View the best growth stocks for 2024 here .

When is Rezolute's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our RZLT earnings forecast .

How were Rezolute's earnings last quarter?

Rezolute, Inc. (NASDAQ:RZLT) issued its quarterly earnings results on Tuesday, February, 13th. The company reported ($0.27) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.27).

What other stocks do shareholders of Rezolute own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Rezolute investors own include Fulcrum Therapeutics (FULC) , VIVUS (VVUS) , Acasti Pharma (ACST) , CymaBay Therapeutics (CBAY) , Entasis Therapeutics (ETTX) , Akero Therapeutics (AKRO) , Cumberland Pharmaceuticals (CPIX) , Evofem Biosciences (EVFM) and Evelo Biosciences (EVLO) .

How do I buy shares of Rezolute?

Shares of RZLT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:RZLT

Rezolute (RZLT) Stock Price, News & Analysis

→ Now Open: Crypto emergency update (From InvestorPlace) (Ad)

Free RZLT Stock Alerts

$3.30

+0.06 (+1.85%)

(As of 04/18/2024 ET)

Compare

Today's Range: $3.24
▼
$3.49
50-Day Range: $1.06
▼
$3.40
52-Week Range: $0.72
▼
$3.63

Volume: 278,502 shs
Average Volume: 302,949 shs
Market Capitalization: $132.43 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $8.80

Get Rezolute alerts:

Rezolute MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 166.7% Upside
$8.80 Price Target
Short Interest: Healthy
0.63% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 1.00
Based on 6 Articles This Week
Insider Trading: Acquiring Shares
$306,601 Bought Last Quarter
Proj. Earnings Growth: Decreasing
From ($1.06) to ($1.15) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.11 out of 5 stars

Medical Sector

324th out of 918 stocks

Pharmaceutical Preparations Industry

135th out of 402 stocks

3.5

Analyst's Opinion

Consensus Rating
Rezolute has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
Rezolute has only been the subject of 4 research reports in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
0.63% of the outstanding shares of Rezolute have been sold short.
Short Interest Ratio / Days to Cover
Rezolute has a short interest ratio ("days to cover") of 0.8, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Rezolute has recently increased by 17.23%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Rezolute does not currently pay a dividend.
Dividend Growth
Rezolute does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for RZLT.

3.9

News and Social Media Coverage

News Sentiment
Rezolute has a news sentiment score of 1.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.49 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 6 news articles for Rezolute this week, compared to 1 article on an average week.
Search Interest
20 people have searched for RZLT on MarketBeat in the last 30 days. This is an increase of 233% compared to the previous 30 days.
MarketBeat Follows
17 people have added Rezolute to their MarketBeat watchlist in the last 30 days. This is an increase of 113% compared to the previous 30 days.

4.2

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Rezolute insiders have bought more of their company's stock than they have sold. Specifically, they have bought $306,601.00 in company stock and sold $0.00 in company stock.
Percentage Held by Insiders
18.20% of the stock of Rezolute is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
82.97% of the stock of Rezolute is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0

Earnings and Valuation

Earnings Growth
Earnings for Rezolute are expected to decrease in the coming year, from ($1.06) to ($1.15) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Rezolute is -3.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Rezolute is -3.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Rezolute has a P/B Ratio of 1.05. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad DTI

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

Click here for the full story

About Rezolute Stock (NASDAQ:RZLT)

Rezolute, Inc., a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It is also developing RZ402, an oral plasma kallikrein inhibitor, which is in clinical trial for the chronic treatment of diabetic macular edema. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.

RZLT Stock Price History

30 days | 90 days | 365 days | Advanced Chart

RZLT Stock News Headlines

March 26, 2024 | insidertrades.com

3 Stocks Insiders Are Buying That Analysts Love (RZLT)

March 20, 2024 | insidertrades.com

Daron Evans Buys 20,000 Shares of Rezolute, Inc. (NASDAQ:RZLT) Stock

April 19, 2024 | InvestorPlace (Ad)

New crypto project uncovers 2,050% in 65 days

During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.

March 19, 2024 | insidertrades.com

Brian Kenneth Roberts Acquires 10,000 Shares of Rezolute, Inc. (NASDAQ:RZLT) Stock

April 18, 2024 | markets.businessinsider.com

Optimistic Buy Rating for Rezolute’s RZ402 Drug Candidate Amid Promising DME Treatment Prospects

April 15, 2024 | investorplace.com

Can You Afford to Ignore These 3 Biotech Stocks Up Over 160% in 2024?

April 10, 2024 | benzinga.com

Rezolute Stock (NASDAQ:RZLT), Analyst Ratings, Price Targets, Predictions

April 10, 2024 | americanbankingnews.com

Rezolute (NASDAQ:RZLT) Receives New Coverage from Analysts at Maxim Group

April 19, 2024 | InvestorPlace (Ad)

New crypto project uncovers 2,050% in 65 days

During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.

April 4, 2024 | insidermonkey.com

Insiders Are Buying These 5 Penny Stocks

March 27, 2024 | finance.yahoo.com

Rezolute Reaches US$75m Market Cap Benefiting Insider Stock Buying

March 20, 2024 | investing.com

Rezolute's chief medical officer buys $18.8k in company stock

March 6, 2024 | globenewswire.com

Rezolute Reports Validation of the Potential Use of RZ358 for Treatment of Non-Islet Cell Tumor Hypoglycemia (NICTH)

February 22, 2024 | benzinga.com

Rezolute Stock (NASDAQ:RZLT) Earnings Dates and Earning Calls

February 16, 2024 | finanznachrichten.de

Rezolute, Inc.: Rezolute Reports Second Quarter Fiscal 2024 Results and Provides Business Update

February 15, 2024 | finance.yahoo.com

We're Keeping An Eye On Rezolute's (NASDAQ:RZLT) Cash Burn Rate

February 13, 2024 | finance.yahoo.com

Rezolute Reports Second Quarter Fiscal 2024 Results and Provides Business Update

February 8, 2024 | markets.businessinsider.com

Buy Rating Affirmed for Rezolute’s RZ358 Based on Untapped Market Potential and Therapeutic Efficacy

January 24, 2024 | msn.com

Rezolute appoints Daron Evans as CFO

January 23, 2024 | msn.com

Rezolute secures innovation passport designation from U.K. for RZ358 treating hypoglycemia

January 23, 2024 | finance.yahoo.com

Rezolute Receives Innovation Passport Designation from the U.K. Innovative Licensing and Access Pathway Steering Group for RZ358 in the Treatment of Hypoglycemia Due to Congenital Hyperinsulinism

December 14, 2023 | finance.yahoo.com

Rezolute Initiates Phase 3 Clinical Study for RZ358 in Congenital Hyperinsulinism

December 13, 2023 | finance.yahoo.com

Rezolute Completes Enrollment of its Phase 2 Study in Diabetic Macular Edema (“DME”)

November 28, 2023 | msn.com

Rezolute (RZLT) Price Target Increased by 5.77% to 8.42

November 24, 2023 | finanznachrichten.de

Rezolute, Inc.: Rezolute Reports First Quarter Fiscal 2024 Results

November 18, 2023 | markets.businessinsider.com

Rezolute’s Promising Drug Pipeline and Market Position Validate Buy Rating: An Analysis of RZ358 and RZ402 Potential

November 17, 2023 | finance.yahoo.com

Rezolute to Participate in BTIG’s 3rd Annual Ophthalmology Day

See More Headlines

Receive RZLT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Rezolute and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 2/13/2024
Today: 4/18/2024
Next Earnings (Estimated): 5/09/2024
Fiscal Year End: 6/30/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:RZLT
CUSIP: N/A
CIK: 1509261
Web: www.rezolutebio.com
Phone: (650) 206-4507
Fax: N/A
Employees: 57
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $8.80
High Stock Price Target: $14.00
Low Stock Price Target: $5.00
Potential Upside/Downside: +166.7%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 5 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.10)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-51,790,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -51.81%
Return on Assets: -48.05%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 12.00
Quick Ratio: 12.00

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $3.15 per share
Price / Book: 1.05

Miscellaneous

Outstanding Shares: 40,130,000
Free Float: 32,413,000
Market Cap: $132.43 million
Optionable: Not Optionable
Beta: 1.29

7 Stocks to Buy And Hold Forever

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Key Executives

Mr. Nevan Charles Elam J.D. (Age 57)
Founder, CEO & Acting Chairman of the Board
Comp: $973.65k
Dr. Brian Kenneth Roberts M.D. (Age 48)
Chief Medical Officer
Comp: $738.86k
Mr. Daron G. Evans M.B.A. (Age 50)
M.S., Chief Financial Officer
Dr. Davelyn Eaves Hood M.B.A.
M.D., Director and Head of Scientific & Patient Affairs
Mr. Michael R. Deperro
Senior VP & Head of Corporate Development
Mr. Michael Covarrubias
Senior VP & Head of Program & Portfolio Management
Mr. Chris Milks
VP & Head of Finance
Dr. Raj Agrawal M.D.
VP & Head of Ophthalmological Clinical Development
Ms. Robyn Sweinhart
VP & Head of Quality
Ms. Erin O'Boyle
Senior VP & Head of Clinical Operations

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

RZLT Stock Analysis - Frequently Asked Questions

Should I buy or sell Rezolute stock right now?: 5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Rezolute in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" RZLT shares.
View RZLT analyst ratings or view top-rated stocks.
What is Rezolute's stock price target for 2024?: 5 brokerages have issued 12-month target prices for Rezolute's shares. Their RZLT share price targets range from $5.00 to $14.00. On average, they predict the company's share price to reach $8.80 in the next twelve months. This suggests a possible upside of 166.7% from the stock's current price.
View analysts price targets for RZLT or view top-rated stocks among Wall Street analysts.
How have RZLT shares performed in 2024?: Rezolute's stock was trading at $0.9925 at the beginning of 2024. Since then, RZLT shares have increased by 232.5% and is now trading at $3.30.
View the best growth stocks for 2024 here.
When is Rezolute's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our RZLT earnings forecast.

How were Rezolute's earnings last quarter?: Rezolute, Inc. (NASDAQ:RZLT) issued its quarterly earnings results on Tuesday, February, 13th. The company reported ($0.27) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.27).
What other stocks do shareholders of Rezolute own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Rezolute investors own include Fulcrum Therapeutics (FULC), VIVUS (VVUS), Acasti Pharma (ACST), CymaBay Therapeutics (CBAY), Entasis Therapeutics (ETTX), Akero Therapeutics (AKRO), Cumberland Pharmaceuticals (CPIX), Evofem Biosciences (EVFM) and Evelo Biosciences (EVLO).
How do I buy shares of Rezolute?: Shares of RZLT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:RZLT) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial